Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 27

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 27
---
 following service as CEO. Mr. Gonzalez’s pay package is consistent with the external competitive market, which the Compensation Committee believes is appropriate based on his leadership in the role and performance track record as CEO. BUSINESS PERFORMANCE HIGHLIGHTS Advanced our strategy through outstanding operational execution and investments in innovation during 2024

| ​                                         | ​ | ​ | ​                                  | ​ | ​ | ​                                      |
| Total Net Revenues                        |   |   | Growth Platform Net Revenues       |   |   | Operating Cash Flow                    |
| $56.3BN                                   | ​ | ​ | $47.3BN                            | ​ | ​ | $18.8BN                                |
| 4.6% operational growth compared to 2023* | ​ | ​ | +18.6% compared to 2023**          | ​ | ​ | in 2024                                |
| ​                                         | ​ | ​ | ​                                  | ​ | ​ | ​                                      |
| ​                                         | ​ | ​ | ​                                  | ​ | ​ | ​                                      |
| Blockbuster Products                      | ​ | ​ | Adjusted R&D Investment            | ​ | ​ | Development Pipeline                   |
| 12                                        | ​ | ​ | $10.8BN                            | ​ | ​ | ~90                                    |
| assets with 2024 net revenues > $1.0BN    | ​ | ​ | increased $3.0BN compared to 2023* | ​ | ​ | active clinical and device programs*** |

The measures set forth in this table were calculated as of 12/31/2024. * Reflects a non-GAAP measure and is adjusted for certain items, which are reconciled in Appendix B. Operational growth is presented at constant currency rates that reflect comparative local currency net revenues at the prior year’s foreign exchange rates. **Growth Platform reflects total net revenues less Humira net revenues. ***Compounds, devices or indications in development individually or under collaboration or license agreements. Strong operational execution

| ● | Total net revenues of $56.3 billion, driven by strong performance from our Growth Platform, reflected a return to top-line growth in the first full year following the U.S. Humira loss of exclusivity (LOE). |

| o | Key asset performance drove Growth Platform net revenues of $47.3 billion, an increase of 18.6% compared to 2023. |

| o | AbbVie’s Growth Platform comprised 84% of total net revenues in 2024